Table 1.
Univariate analysis of variables with influence on survival and relapse
| Characteristics | n (%) | EFS | OS | ||
|---|---|---|---|---|---|
| 5-year survival (%) | p value | 5-year survival (%) | p value | ||
| Age Group | |||||
| 60 ≤ | 92 (63.1) | 64.6 | 0.002 | 76.3 | < 0.001 |
| 60 > | 54 (36.9) | 39.0 | 38.8 | ||
| Sex | |||||
| female | 64 (43.8) | 59.1 | 0.638 | 63.6 | 0.876 |
| male | 82 (56.2) | 52.9 | 61.7 | ||
| Localization | |||||
| proximal | 95 (65.0) | 51.0 | 0.304 | 57.7 | 0.135 |
| distal | 51 (35.0) | 61.5 | 69.6 | ||
| H. Pylori (n = 70) | |||||
| no | 59 (84.2) | 59.3 | 0.687 | 61.7 | 0.632 |
| yes | 11 (15.8) | 80.0 | 80.8 | ||
| IPI risk group | |||||
| low | 67 (45.8) | 76.6 | 82.6 | ||
| intermediate | 65 (44.5) | 46.0 | 0.001 | 45.4 | < 0.001 |
| high | 14 (9.7) | 35.1 | 30.8 | ||
| Performance score | |||||
| 0 and 1 | 120 (82.1) | 53.3 | 0.037 | 68.6 | 0.013 |
| 2 | 26 (17.9) | 36.5 | 42.3 | ||
| LDH | |||||
| normal | 92 (63.0) | 53.1 | 0.404 | 62.6 | 0.687 |
| high | 54 (37.0) | 55.3 | 55.6 | ||
| Albumin | |||||
| < 3.5 wg/dl | 50 (34.2) | 16.0 | 0.029 | 47.0 | 0.028 |
| > 3.5 wg/dl | 96 (65.8) | 69.7 | 76.5 | ||
| Haemoglobin | |||||
| < 12 wg/dl | 62 (42.4) | 36.0 | 0.004 | 47.3 | 0.036 |
| > 12 wg/dl | 84 (57.6) | 61.5 | 64.1 | ||
| Stage (Lugano) | |||||
| I–II | 108 (73.9) | 58.2 | 0.023 | 69.0 | 0.001 |
| IV | 38 (26.1) | 46.1 | 42.1 | ||
| Treatment modalities (n = 140) | |||||
| CT | 63 (43.1) | 53.9 | 59.3 | ||
| CT + RT | 38 (26.0) | 47.0 | 0.707 | 48.8 | 0.124 |
| S + CT | 26 (17.9) | 66.5 | 68.2 | ||
| S + CT + RT | 13 (9.0) | 57.7 | 92.3 |
CT – chemotherapy; RT – radiotherapy; S – surgery; IPI – International Prognostic Index